IL115223A0 - Preparation containing antiresorptive compounds for use in the treatment of osteoporosis - Google Patents

Preparation containing antiresorptive compounds for use in the treatment of osteoporosis

Info

Publication number
IL115223A0
IL115223A0 IL11522395A IL11522395A IL115223A0 IL 115223 A0 IL115223 A0 IL 115223A0 IL 11522395 A IL11522395 A IL 11522395A IL 11522395 A IL11522395 A IL 11522395A IL 115223 A0 IL115223 A0 IL 115223A0
Authority
IL
Israel
Prior art keywords
osteoporosis
treatment
preparation containing
antiresorptive
compounds
Prior art date
Application number
IL11522395A
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of IL115223A0 publication Critical patent/IL115223A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL11522395A 1994-09-09 1995-09-08 Preparation containing antiresorptive compounds for use in the treatment of osteoporosis IL115223A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30398194A 1994-09-09 1994-09-09

Publications (1)

Publication Number Publication Date
IL115223A0 true IL115223A0 (en) 1995-12-31

Family

ID=23174525

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11522395A IL115223A0 (en) 1994-09-09 1995-09-08 Preparation containing antiresorptive compounds for use in the treatment of osteoporosis

Country Status (9)

Country Link
EP (1) EP0779813A4 (en)
JP (1) JPH10505091A (en)
KR (1) KR970705399A (en)
CN (1) CN1157566A (en)
AU (1) AU686019B2 (en)
CA (1) CA2199251A1 (en)
IL (1) IL115223A0 (en)
PE (1) PE48597A1 (en)
WO (1) WO1996007418A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
HN1996000101A (en) * 1996-02-28 1997-06-26 Inc Pfizer COMBINED THERAPY FOR OSTEOPOROSIS
WO2001097788A2 (en) 2000-06-20 2001-12-27 Novartis Ag Method of administering bisphosphonates
US20040014726A1 (en) * 2000-10-27 2004-01-22 Thua Osterman Method for the preparation of a pharmaceutical composition, and its use
BRPI0618469A2 (en) 2005-11-10 2011-08-30 Univ Michigan Tech black bear parathyroid hormone and methods of using black bear parathyroid hormone
CA2782640A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
SK74594A3 (en) * 1991-12-17 1995-01-12 Procter & Gamble Pharma Treatment for treating of osteoporosis

Also Published As

Publication number Publication date
CN1157566A (en) 1997-08-20
WO1996007418A1 (en) 1996-03-14
KR970705399A (en) 1997-10-09
AU3627795A (en) 1996-03-27
EP0779813A1 (en) 1997-06-25
EP0779813A4 (en) 1998-05-06
AU686019B2 (en) 1998-01-29
PE48597A1 (en) 1997-12-11
CA2199251A1 (en) 1996-03-14
JPH10505091A (en) 1998-05-19

Similar Documents

Publication Publication Date Title
GB9407135D0 (en) Treatment of osteoporosis
PL318760A1 (en) Spiroazabicyclo compounds useful in medical treatment
ZA988886B (en) Formulation for treatment of osteoporosis
AU4154796A (en) Compounds for the photodecontamination of pathogens in blood
IL112455A0 (en) Combination treatment for osteoporosis
HUP0102556A3 (en) Benzenesulfonamide-derivatives and their use as medicaments and process for the preparation of the compounds
EP0703282A3 (en) Composition for surface treatment
EP0699695A3 (en) Process for the preparation of copolyacetals
ZA954324B (en) Process for the preparation of 3-aryluracils
IL113248A0 (en) Use of alpha - 1c specific compounds
ZA951322B (en) Process for the preparation of polyalkyl-1-oxa-diazaspiro-decane compounds
GB9423868D0 (en) Compounds for use in medicine
IL121730A0 (en) Process for the preparation of 2'-fluoro-5-methyl-beta-L-arabino-furanosyluridine
GB9424694D0 (en) Compounds for use in medicine
GB9509826D0 (en) Process for the preparation of imidazolutidine
IL115223A0 (en) Preparation containing antiresorptive compounds for use in the treatment of osteoporosis
IL115224A0 (en) Preparations for use in the treatment of osteoporosis
HUP9903852A3 (en) Process for the preparation of contrast agents
ZA891894B (en) Composition for the treatment of osteoporosis in humans
IL115225A0 (en) Preparations containing estrogen compounds for use in the treatment of osteoporosis
EP0755262A4 (en) Composition for the treatment of lung disease
EP0724842A3 (en) Preparation for the treatment of obesity
ZA9510894B (en) Process for the preparation of chloromethylpyridines
IL116493A0 (en) Process for the preparation of sameridine
EP0460690A3 (en) Use of phenolsulfophthaline derivatives for the treatment of osteoporosis